为了使您在Abcam官网的浏览体验更顺畅，请使用最新版本的浏览器比如 Google Chrome
The details of the immunogen for this antibody are not available.
In vivo and in vitro treatment with the 53-6.7 monoclonal antibody effectively depletes CD8 alpha+ cells. The 53-6.7 monoclonal antibody also blocks allogeneic help specific for class I MHC antigens and T cell responses to IL-2.
Our Abpromise guarantee covers the use of ab39850 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.
In vivo and in vitro depletion of CD8a+ cells and fractionation of CD8a+ T cells.
|Flow Cyt||Use 0.2µg for 106 cells. ab136584-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.|
|IHC-Fr||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
ab39850 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"